FILE PHOTO: Bytedance logo is seen in this illustration taken February 8, 2025.

ByteDance has completed a $290 million fundraising round for its newly spun-off AI drug discovery unit, achieving a valuation of $1.5 billion. The inaugural external funding event establishes Anew Labs as a standalone entity independent of its parent company's core operations. ByteDance will retain a 56% stake in the newly formed venture following the transaction.